Asma e DPOC: duas faces de um mesmo dado?
Asthma and COPD: two faces sides of the same dice?
Hisbello S. Campos
Resumo
Os imbricados processos patogênicos da asma e da doença pulmonar obstrutiva crônica (DPOC) têm mecanismos comuns que envolvem redes genéticas, subclasses de linfócitos, diversas citocinas e quimiocinas, gerando comportamento alterado de todas as células estruturais e funcionais do trato respiratório. Uma parte das centenas de genes que vêm sendo implicados na patogenia da asma e da DPOC é comum às duas. Aparentemente, eles formam uma grande rede, e sua ação conjunta está associada às alterações presentes nas duas disfunções respiratórias. Dado que parte da base genética e muitos processos inflamatórios são comuns às duas doenças, pode-se supor que elas componham uma única entidade, que pode se apresentar de diversas formas.
Palavras-chave
Abstract
The overlapping pathogenic processes of asthma and chronic obstructive pulmonary disease (COPD) have common mechanisms involving genetic networks, lymphocyte subclasses, several cytokines and chemokines, generating abnormal behavior of all structural and functional cells of the respiratory tract. Part of hundreds of genes implicated in the pathogenesis of asthma and COPD are the same. Apparently, they form a large network and their joint action is associated with several changes in both respiratory disorders. As part of their genetic basis is common and many inflammatory processes are similar in both disorders, we may assume that they form a single entity that may occur in different ways.
Keywords
References
1. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598-604.
2. Irvin CG. Neutrophils, airway hyperresponsiveness and COPD: true, true and related? Eur Respir J. 2012;40(5):1067-9.
3. Brightling CE. Clinical applications of induced sputum. Chest. 2006;129(5):1344-8.
4. Barker BL, Brightling CE. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. ClinSci (Lond). 2013;124(6):371‑87.
5. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;Suppl:S214-9.
6. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728-35.
7. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138(5):1140-7.
8. Orie NG. The Dutch hypothesis. Chest. 2000;117(5Suppl 1):2999S.
9. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, et al. SAPALDIA Team. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006;61(8):671-7.
10. Postma DS, Kerkof M, Boezen HM, Koppelmann GH. Asthma and chronic obstructive pulmonary disease: common genes, common environments? Am J Respir Crit Care Med. 2011;183:1588-94.
11. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax. 2014;69(9):805-10.
12. Kaneko Y, Yatagai Y, Yamada H, Iijima H, Masuko H, Sakamoto T, et al. The search for common pathways underlying asthma and COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:65-78.
13. Tabak C, Feskens EJ, Heederik D, Kromhout D, Menotti A, Blackburn HW. Fruit and fish consumption: a possible explanation for population differences in COPD mortality (The Seven Countries Study). Eur J Clin Nutr. 1998;52(11):819-25.
14. Tabak C, Arts IC, Smit HA, Heederik D, Kromhout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones: the MORGEN Study. Am J Respir Crit Care Med. 2001;164(1):61-4.
15. Pfeffer PE, Hawrylowicz CM. Vitamin D and lung disease. Thorax. 2012;67(11):1018-20.
16. Royce SG, Le Saux CJ. Role of caveolin-1 in asthma and chronic inflammatory respiratory diseases. Expert Rev Respir Med. 2014;8(3):339-47.
17. Walker ML, Holt KE, Anderson GP, Teo SM, Sly PD, Holt PG, et al. Elucidation of pathways driving asthma pathogenesis: development of a systems-level analytic strategy. Front Immunol. 2014;5(447):1‑16.
18. Shaykhiev R, Crystal RG. Innate immunity and chronic obstructive pulmonary disease: a mini-review. Gerontology. 2013;59(6):481-9.
19. Pace E, Giarratano A, Ferraro M, Bruno A, Siena L, Mangione S, et al. TLR4 upregulation underpins airway neutrophilia in smokers with chronic obstructive pulmonary disease and acute respiratory failure. Hum Immunol. 2011;72:54-62.
20. Mortaz E, Adcock IM, Ito K, Kraneveld AD, Nijkamp FP, Folkerts G. Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J. 2010;36:1143-54.
21. Aryan Z, Holgate ST, Radzioch D, Rezaei N. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol. 2014;164(1):46-63.
22. Durrant DM, Metzger DW. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest. 2010;39:526-49.
23. Zoratti E, Havstad S, Wegienka G, Nicholas C, Bobbitt KR, Woodcroft KJ, et al. Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles. Ann Allergy Asthma Immunol. 2014;113(1):25-30.
24. Longphre M, Li D, Gallup M, Drori E, Ordoñez CL, Redman T, et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest. 1999;104(10):1375-82.
25. Halwani R, Al-Muhsen S, Hamid Q. T helper 17 cells in airway diseases. Chest. 2013;143(2):494-501.
26. Larche M. Regulatory T cells in allergy and asthma. Chest. 2007;132:1007-14.
27. Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):40-50.
28. Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlate with chronic obstructive pulmonary disease severity. Am J Pathol. 2007;171:767-76.
29. Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, et al. Cytotoxic potential of lung CD8+ T-cells increases with chronic obstructive pulmonary disease and in vitro stimulation by IL-18 or IL-15. J Immunol. 2010;184:6504-13.
30. Lethbridge MW, Kemeny DM, Ratoff JC, O'Connor BJ, Hawrylowicz CM, Corrigan CJ. A novel technique to explore the functions of bronchial mucosal T-cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity. Clin Exp Immunol. 2010;161:560-9.
31. Pichavant M, Rémy G, Bekaert S, Le Rouzic O, Kervoaze G, Vilain E, et al. Oxidative stress-mediated iNKT-cell activation is involved in COPD pathogenesis. Mucosal Immunol. 2014;7(3):568-78.
32. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, Tsukaguchi K, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest. 1997;112:505-10.
33. Virchow JCJr, Kroegel C, Walker C, MAtthys H. Inflammatory determinants of asthma severity: mediator and cellular changes in bronchoalveolar lavage fluid of patients with severe asthma. J Allergy Clin Immunol. 1996;98:527-33.
34. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: Causes and consequences. Trends Mol Med. 2010;16:238-46.
35. Rodier F, Coppé JP, Patil CK, Hoeijmakers WA, Muñoz DP, Raza SR. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973-9.
36. Paraskakis E, Sourvinos G, Passam F, Tzanakis N, Tzortzaki EG, Zervou M, et al. Microsatelite DNA instability in COPD. Chest. 1999;116:47-51.
37. Mehrotra P, Riley JP, Patel R, Li F, Voss L, Goenka S. PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. J Biol Chem. 2011;286:1767-76.
38. Ammit AJ, PAnetierri RJ. Invited review: the circle of life: cell cycle regulation in airway smooth muscle. J Appl Physiol. 2001;91:1431-7.
39. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102-14.
40. Angulo M, Lecuona E, Sznaider JI. Role of microRNA in lung diseases. Arch Broncopneumol. 2012;48(9):325-30.
41. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax. 2012;67:122‑31.
42. Williams AE, Larner-Svensson H, Perry MM, Campbell GA, Herrick SE, Adcock IM, et al. MicroRNA expression profiling in mild asthmatics human airways and effect of corticosteroid therapy. PLoS One. 2009;4(6):e5889.
43. dos Santos G, Kutuzov MA, Ridge KM. The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L627‑33.
44. Brusselle G, Provoost S, Bracke K, Kuchmiy A, Lamkanfi M. Inflammasomes in respiratory disease: from bench to bedside. Chest. 2014;145(5):1121-33.
45. Willart MA, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. 2009;39(1):12-9.
46. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012 4;18(5):673-83.
47. Matsumoto K, Inoue H. Viral infections in asthma and COPD. Respir Investig. 2014;52(2):92-100.
48. Sharma G, Hanania NA, Shim YM. The aging imune system and its relationship to the development of chronic obstructive pulmonar disease. Proc Am Thorac Soc. 2009;6:573-80.
49. Adnot S. Cell senescence and pathophysiology of chronic lung diseases: role in chronic obstructive pulmonary disease. Bull Acad Natl Med. 2014;198(4-5):659-71.
50. Bush A. Lung Development and Aging. Ann Am Thorac Soc. 2016;13(Supplement_5):S438-S446.
51. Poon AH, Houseman EA, Ryan L, Sparrow D, Vokonas PS, Litonjua AA. Variants of asthma and chronic obstructive pulmonary disease genes and lung function decline in aging. J Gerontol A Biol Sci Med Sci. 2014;69(7):907‑13.
52. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol. 2010;10:838-48.
53. Sharma G, Hanania NA, Shim YM. The aging imune system and its relationship to the development of chronic obstructive pulmonar disease. Proc Am Thorac Soc. 2009;6:573-80.
54. Lee N, Shin MS, Kang I. T-cell biology in aging, with a focus on lung disease. J Gerontol A Biol Sci Med. 2012;67:254-63.
55. Hanson C, Rutten EP, Wouters EF, Rennard S. Diet and vitamin D as risk factors for lung impairment and COPD. Transl Res. 2013;162(4):219-36.
56. Tabak C, Feskens EJ, Heederik D, Kromhout D, Menotti A, Blackburn HW. Fruit and fish consumption: a possible explanation for population differences in COPD mortality (The Seven Countries Study). Eur J Clin Nutr. 1998;52(11):819-25.
57. Tabak C, Arts IC, Smit HA, Heederik D, Kromhout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones: the MORGEN Study. Am J Respir Crit Care Med. 2001;164(1):61-4.
58. García de Tena J, El Hachem Debek A, Hernández Gutiérrez C, Izquierdo Alonso JL. The role of vitamin D in chronic obstructive pulmonary disease, asthma and other respiratory diseases. Arch Broncopneumol. 2014;50:179-84.
59. Pfeffer PE, Hawrylowicz CM. Vitamin D and lung disease. Thorax. 2012;67(11):1018-20.
60. Foong RE, Zosky GR. Vitamin D deficiency and the lung: disease initiator or disease modifier? Nutrients. 2013; 5(8):2880-900.
61. Moberg M, Vestbo J, Martinez G, Lange P, Ringbaek T. Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. Scientific World Journal. 2014;2014:140736.
62. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Fenger RV, et al. Vitamin D status and chronic obstructive pulmonary disease: a prospective general population study. PLoS One. 2014;9(3):e90654.
63. Zhang LL, Gong J, Liu CT. Vitamin D with asthma and COPD: not a false hope? A systematic review and meta-analysis. Genet Mol Res. 2014;13(3):7607-16.
64. Huang H, Porpodis K, Zarogoulidis P, Domvri K, Giouleka P, Papaiwannou A, et al. Vitamin D in asthma and future perspectives. Drug Des Devel Ther. 2013;7:1003-13.
65. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2009;6:638-47.
66. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245‑57.
67. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J COPD. 2014;9:871-88.
68. Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of co-morbities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008. COPD. 2013;10(3):324-32.
Submitted date:
03/09/2018
Accepted date:
07/09/2018
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email